Supplemental Table E-1. Summary of Included Randomized Clinical Trials

Supplement

Supplemental Table e-1. Summary of included randomized clinical trials

Study / Year / Country / Population / Intensive Tx (n, target) / GuidelineTx(n, target)
ICH ADAPT 13 / 2013 / Canada / ICH<24h of onset, SBP>150 mmHg, Age> 18y / 39 / SBP<150 mmHg / 36 / SBP<180 mmHg
INTERACT I 14 / 2008 / Multicenter / ICH<6h of onset, SBP=150-220 mmHg, Age> 18y / 203 / SBP=140 mmHg / 201 / SBP=180 mmHg
INTERACT II 15 / 2013 / Multicenter / ICH<6h of onset, SBP=150-220 mmHg, Age> 18y / 1382 / SBP=140 mmHg / 1412 / SBP=180 mmHg
Koch et al 16 / 2008 / USA / ICH<6h of onset, MAP>110 mmHg, Age> 18y / 21 / MAP<110 mmHg / 21 / MAP= 110-130 mmHg

Tx: treatment; n: number, h: hours, y: years, ICH: intracerebral hemorrhage, SBP: systolic blood pressure, MAP: mean arterial pressure

Supplemental Table e-2. Baseline characteristics across the different arms of randomized controlled trials.

Baseline / ICH ADAPT / INTERACT I / INTERACTII / Koch et al
Characteristic / Guideline / Intensive / Guideline / Intensive / Guideline / Intensive / Guideline / Intensive
Age (years) / 68±11.1 / 70.7±12.5 / 62±13 / 63±12 / 64.1±12.6 / 63±13.1 / 60±11 / 61.2±13
Male (%) / 77.8 / 66.7 / 69.1 / 60.6 / 61.8 / 64.2 / 66.7 / 42.8
Hypertension (%) / 75 / 66.7 / 74.1 / 74.4 / 72.5 / 72.4 / 90 / 85
Antiplatelets (%) / 0 / 10.2 / 6.5 / 9.3 / 9.9 / 8.8 / 19 / 33.3
Anticoagulants (%) / 8.3 / 2.5 / 0.5 / 1.5 / 2.2 / 3.6 / 0 / 4.7
NIHSS / 11
(5,5-15,5) / 10
(6-18) / 9
(5-16) / 9
(5-14) / 11
(6-16) / 10
(6-15) / 10.9±6.5 / 12±7
GCS / 15
(6-15) / 14
(4-15) / 14
(12-15) / 14
(13-15) / 14
(12-15) / 14
(12-15) / 15
(10-15) / 13.5
(9-15)
Onset to randomization (hrs) / 8.54
(3.8-15.9) / 7.8
(3.3-16.8) / 3.4
(2.5-4.5) / 3.4
(2.5-4.5) / 3.7
(2.9-4.7) / 3.7
(2.8-4.8) / 3.2 ± 2.2 / 3.1 ± 2.2

NIHSS: National Institutes of Health Stroke Scale; GCS: Glasgow Coma Scale; SBP: systolic blood pressure; MAP: mean, arterial pressure; hrs: hours

Supplemental Table e-3. Quality assessment of the individual randomized clinical trials that were included in the meta-analysis

Risk of bias / ICH ADAPT / INTERACT I / INTERACT II / Koch et al
Sequence generation / Low / Low / Low / Unclear
Allocation concealment / Low / Low / Low / Low
Blinding of participants and personnel / High / High / High / High
Blinding of outcome assessors / Low / Low / Low / Low
Incomplete outcome data / Low / Low / Low / Low
Selective outcome reporting / Low / Low / Low / Low
Other sources of bias / Low / Low / Low / Low

low: low risk of bias; high: high risk of bias; unclear: unclear risk of bias

Supplemental e-Figure. Funnel plot of included studies